Banerjee S, Katz J, Levitz M, Finlay T H
Department of Obstetrics and Gynecology, New York University, School of Medicine, New York 10016.
Cancer Res. 1991 Feb 15;51(4):1092-8.
Levels of estradiol 17 beta-ester hydrolytic activity in the breast cyst fluid (BCF) from 25 different women with fibrocystic disease of the breast were found to vary over a wide range (0-2.4 nmol/min/mg protein for estradiol acetate). On the basis of electrophoretic mobility on agarose gels, the activity from different individuals appeared to be identical. The esterase activity from a single BCF sample was purified to near homogeneity by differential ammonium sulfate precipitation, ion-exchange, and hydrophobic interaction chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis, after the final purification step, showed two bands with molecular weights of approximately 22,000 and 23,000, neither of which was immunoreactive with a rabbit antibody raised to a crude esterase-free BCF preparation. Esterase activity could be demonstrated after extraction and renaturation of the protein eluted from the Mr 22,000 band. Resolution of the gel, however, was not good enough to rule out the presence of esterase activity in the Mr 23,000 protein. High performance liquid chromatography gel exclusion chromatography indicated a molecular weight of 90,000-95,000 for the esterase activity in crude BCF and approximately 225,000 for the purified activity, suggesting the native protein to be a tetramer which aggregated during purification. Although the natural substrate of the BCF esterase is unknown, the enzyme is able to cleave a variety of esters including acetate, valerate, and stearate esters of estradiol and p-nitrophenyl hexanoate. It is completely inhibited by diisopropylflurophosphate and diethylnitrophenyl phosphate and partially inhibited by NaF and ebelactone. The substrate and inhibitor profile of the enzyme indicates that it is a "B"-type carboxylesterase and not a protease. A comparison of the properties of the BCF esterase with those of esterases from the formed elements of the blood or from plasma suggests that the BCF esterase is not of blood origin and is probably derived from the cyst itself. Physiologically inactive lipoidal estrogens have been shown to be present in many human body fluids and tissues and it is possible that these esters serve as storage forms of the active hormone in hormonally sensitive tissues where the free steroid could be regenerated by hydrolysis.
在25名患有乳腺纤维囊性疾病的不同女性的乳腺囊肿液(BCF)中,发现17β-雌二醇酯水解活性水平在很宽的范围内变化(乙酸雌二醇的活性为0 - 2.4 nmol/分钟/毫克蛋白质)。基于在琼脂糖凝胶上的电泳迁移率,来自不同个体的活性似乎是相同的。通过硫酸铵分级沉淀、离子交换和疏水相互作用色谱法,将单个BCF样品中的酯酶活性纯化至接近均一。在最终纯化步骤后,十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳显示出两条带,分子量分别约为22,000和23,000,其中任何一条带都不能与针对无粗酯酶的BCF制剂产生的兔抗体发生免疫反应。从分子量22,000条带洗脱的蛋白质经提取和复性后可证明酯酶活性。然而,凝胶的分辨率不足以排除分子量23,000的蛋白质中存在酯酶活性。高效液相色谱凝胶排阻色谱表明,粗BCF中的酯酶活性分子量为90,000 - 95,000,纯化后的活性分子量约为225,000,这表明天然蛋白质是一种四聚体,在纯化过程中发生了聚集。虽然BCF酯酶的天然底物尚不清楚,但该酶能够裂解多种酯,包括雌二醇的乙酸酯、戊酸酯和硬脂酸酯以及对硝基苯基己酸酯。它完全被二异丙基氟磷酸酯和二乙基硝基苯基磷酸酯抑制,部分被氟化钠和埃博内酯抑制。该酶的底物和抑制剂谱表明它是一种“B”型羧酸酯酶,而不是蛋白酶。将BCF酯酶的特性与来自血液有形成分或血浆的酯酶的特性进行比较表明,BCF酯酶并非源自血液,可能来自囊肿本身。已证明生理上无活性的脂质雌激素存在于许多人体体液和组织中,并且有可能这些酯在激素敏感组织中作为活性激素的储存形式,在这些组织中游离类固醇可通过水解再生。